United Therapeutics Corp

UTHR

Equity

ISIN null / Valor 848383

NASDAQ (2026-03-31)

USD 592.98+0.79%

United Therapeutics Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

United Therapeutics Corporation is a publicly traded biotechnology company headquartered in Silver Spring, Maryland, that develops, manufactures and commercializes therapies for pulmonary arterial hypertension (PAH) and other serious conditions. Its commercial portfolio is built around multiple formulations of the prostacyclin analogue treprostinil — including Remodulin (parenteral), Tyvaso (inhaled) and Orenitram (oral) — which account for the bulk of its revenue, and the company also markets dinutuximab (Unituxin) for high‑risk neuroblastoma. Alongside drug development and sales, United Therapeutics has expanded into organ manufacturing and xenotransplantation through subsidiaries working on genetically engineered porcine organs and lung bioengineering, and it runs substantial in‑house manufacturing operations to support both marketed products and a research pipeline aimed at addressing organ failure and other unmet needs.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

92.4%1Y

165%3Y

255%5Y

Performance

46.3%1Y

35.2%3Y

34.6%5Y

Volatility